TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in office diastolic and systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-stent Late Loss (LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: California Verbal Learning Test- 2nd Edition (CVLT-II): Learning and Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Satisfaction with the PRISMS program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived ease of use of the PRISMS program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of sessions attended throughout the intervention period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days self-monitoring weight in LoseIt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days self-monitoring weight-related behaviors in LoseIt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost-Utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Galvanic skin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol levels measured in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area under the concentration-time curve at different time points)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concerns about falling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: avoidance of activities due to concerns about falling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects with an average of 3 or more SCBM per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Short Physical Performance Battery (SPPB)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biochemically Verified 7-day Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participation of daily life
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Level of [14C]-ETC-1002 in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary artery mean pressure at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful intubation during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual acuity (change from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Medication Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immunologic feature of AMI patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Bone Pain (All Grades)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Corneal Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Worst Visual Analog Scale(VAS) Dry Eye Symptom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: median reaction time during the second 15 minutes of vigilance subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coma Recovery Scale-Revised scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glasgow Outcome Scale-Extended
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6-Minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score of neurocognitive measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post Operative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Mean Number of Accidents
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of body fat percentages from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of blood lipid profiles from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Emergent Adverse Event (TEAE) Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of optimal care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of non optimal care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Five-year Disease-free Survival (DFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Immune Responses to the Study Vaccine Regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Anti-AMG 592 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold Change from Baseline in Absolute Cell Counts of Regulatory T Cells (Tregs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold Change from Baseline in Absolute Cell Counts of Conventional T Cells (Tcons)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold Change from Baseline in Absolute Cell Counts of Natural Killer Cells (NKs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AEP differences during sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulmonary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in systemic arterial saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants who achieve HIV remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histologic measurement of cavitary ablation lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase of pubes as measured by Tanner stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stem-shaft-angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Force measured in newtons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak flow data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: WORMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Willingness of patients to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety number of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol elimination time constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Plasma HIV-1 RNA Below 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Unscheduled hospitalization for heart failure progression
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean cerebral perfusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abutment screw loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC0-t and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ROM and Biodex Isokinetic Strength Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to full activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of the characteristics of Lichen sclerosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effects on the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psycho-pedagogic score (ECIPE score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients reaching complete oncological treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sucking efficiency of the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stress level of the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bilirubin level of the newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Instrumental vaginal births
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Meares-Stamey evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Heart Rate to Post Stimulation Period Visit 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Heart Rate to Post Stimulation Period Visit 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline O2 Saturation to Post Stimulation Period Visit 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline O2 Saturation to Post Stimulation Period Visit 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute lower respiratory illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Low Birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Stress as assessed by the Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of jaundice clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence-Free Survival (RFS) at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: scan score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of endothelial dysfunction measured by flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Electrocardiogram (ECG): Ventricular rate, PR interval, qRS duration, QT, QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Beck Depression Inventory (BDI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tooth Survival
Endpoint domain: Mortality/survival
Primary endpoint: Electrical Impedance Myography Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defocus curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mass spectrometric profile of exhaled breath patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Concentration of exhaled metabolites of pharmacotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Hearing Loss
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With BICLA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LH Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Secretion of AAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HIV transmission
Endpoint domain: Mortality/survival
Primary endpoint: CoMDA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first episode of culture-confirmed influenza illness
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of early maladaptive schemas
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BFI-T score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Serum YKL-40 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Global Improvement Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Molecular effects on tumor microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Fat Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Anesthesia as Measured by Pin Prick Test (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of Anesthesia as Measured by Heat Sensation Threshold (QST Heat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: length of intravenous azithromycin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity (HI-titers after 2 and 3 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Complete or Almost Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resectability of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of alternating therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of responders to renal denervation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in patient's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wrist swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-bleeding Within 4 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients adherent to the study treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean COMFORT score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptomatic Recurrent VTE
Endpoint domain: Mortality/survival
Primary endpoint: Displacement of the center of pressure of the body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional mobility on the Timed Up & Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static and dynamic balance on the Berg Balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery time from motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Insulin signaling in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms of a Common Cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of serious arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Language/Words acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of life space measured with the Life Space Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Assessment of vision under low luminance conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in contrast sensitivity functions between controls and patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Sexual Violence Victimization
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Volume of cervical drainage after total thyroidectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global and regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) for Lisdexamfetamine Dimesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for Lisdexamfetamine Dimesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for D-amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality prediction accuracy
Endpoint domain: Mortality/survival
Primary endpoint: Average number of terminal hairs per graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants experiencing dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Medication Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Free Cortisol (UFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitive block duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of aspirate specimen yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c from baseline to 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in LDL from baseline to 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in systolic and diastolic blood pressure from baseline to 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in body mass index (BMI) from baseline to 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distribution of plantar pressures during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with abnormalities in clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormalities in vital sign parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of total marrow irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthostatic challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hematological toxicities > grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 extrapolated to time infinity (AUC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of iron states
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Adverse Events Leading to Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Successful recruitment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Psoriatic Plaque Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: atherosclerotic diseases prevalence assessed by coronary artery calcium scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: atherosclerotic diseases prevalence assessed by pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: atherosclerotic diseases prevalence assessed by high-sensitive CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: atherosclerotic diseases prevalence assessed by high-sensitive cardiac Troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes